Shots:

• The ongoing P-II AAVIATE & ALTITUDE trial evaluates RGX-314 using suprachoroidal delivery in patients with wet AMD & DR without CI-DME, respectively
• In the P-II AAVIATE trial, the therapy showed stable visual acuity & retinal thickness, >70% reduction in anti-VEGF treatment burden @6mos., 40% of patients were anti-VEGF inj.-free & was well tolerated in cohort 2. The results from cohort 1 in the P-II ALTITUDE trial showed stable visual acuity @3mos. after one-time treatment of RGX-314
• RGX-314 has developed with NAV AAV8 vector that encodes an Ab fragment & inhibits VEGF. The therapy is being investigated as a one-time treatment for wet AMD, DR & other chronic retinal conditions

  Ref: PR Newswire | Image: Regenxbio